Key clinical point: Pre-clinical data suggests the novel histone deacetylase (HDAC) inhibitor chidamide could be effective in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) being retreated with rituximab.

Major finding: Combined therapy with rituximab and chidamide showed inhibited tumor growth and rituximab-induced cell death in both in vivo and in vitro models.

Study details: A pre-clinical study examining the effects of chidamide as a novel HDAC inhibitor in DLBCL.

Disclosures: The study was funded by the National Natural Science Foundation of China and the Kay Kendall Leukaemia Fund, UK. The authors reported having no conflicts of interest.